Aspen Pharmacare’s Revenue Up 33% In H113
News: South African drugmaker Aspen Pharmacare's revenues increased 33% to ZAR12bn (US$1.1bn) in H113, ended December 31 2013. The company's operating profit rose 16% to ZAR2.9bn (US$269mn) during the period, after taking into account transaction costs of ZAR143mn (US$13.3mn) associated with new business acquisitions that took place in H113. The company's normalised headline earnings, including adjustments for specific non-trading items, increased 23% to ZAR2.1bn (US$195mn) during the reported period. Aspen Pharmacare's revenue from its domestic market rose 8% to ZAR3.8bn (US$353mn) in H113, while its operating profit before amortisation, including adjustments for specific non-trading items remained unchanged at around ZAR1bn (US$93mn). Revenue from the company's international business grew 94% to ZAR3.4bn (US$316mn) during the reported period, while its earnings before interest, taxes and amortisation increased 79% to ZAR1.1bn (US$102mn).